VM 902

Drug Profile

VM 902

Alternative Names: VM 902A

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator VM Discovery
  • Developer Purdue Pharma
  • Class Small molecules
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 25 Nov 2016 Purdue Pharma suspends enrolment in its phase II trial for Pain in USA (NCT02847702)
  • 01 Aug 2016 Phase-II clinical trials in Pain in USA (PO) (NCT02847702)
  • 08 Sep 2015 Purdue Pharma acquires the intellectual property rights of VM 902 and related compounds from VM Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top